Aim: To study the effect of a combination of functional foods on gut microbiota in subjects with metabolic syndrome. Subjects that met the metabolic syndrome criteria were enrolled in a double-blind, parallel-arm, placebo-control study. The subjects were randomized to receive a dietary portfolio (DP) or placebo (P) treatment for 2 mo. The primary endpoint was to study the effect of a DP on gut microbiota. Secondary endpoints were biochemical and anthropometric parameters, LPS, insulin, leptin, area under the curve for glucose and insulin.
This study was a single-center, randomized, controlled, double-blind, parallel versus placebo that consisted of five visits. The first visit was a screening evaluation to determine whether subjects met the inclusion criteria. The selected subjects were invited to a second visit that consisted of a medical history, 2-h oral glucose tolerance test (OGTT), the collection of stool samples for DNA isolation and collection of 5 ml blood sample. The participants received during the first stage, a low saturated fat diet (LSFD) for 15 days. In the third visit and second stage of dietary treatment, subjects were randomized to receive the dietary portfolio (DP) or placebo (P) treatment + an LSFD accompanied of a reduced energy diet for 1 mo. In the fourth visit, with a 1 mo interval, dietary assessment and compliance to the DP or P were evaluated. During each follow-up visit, a 24-h dietary recall was collected, a physical activity questionnaire was filled out and anthropometric and clinical parameters were assessed. In the fifth visit, a 2 -h oral glucose tolerance test (OGTT) was performed, and a stool sample for DNA isolation and 5 ml blood were collected. Dietary intervention in the first stage, the participants consumed a reduced-energy diet tailored to provide a 500-kcal/d deficit as recommended by NIH with respect to their habitual diet for 15 days. The diet plan consisted in 50-60% carbohydrates, 15% protein, 25-35% fat, \<7% saturated fat, ≤ 200 mg, 20-35 g fiber, 2000 mg/d sodium based on total energy. In the second stage, the participants continued to consume the reduced energy diet with the addition of a combination of functional foods (DP). The DP provided 200 kcal that were subtracted from the diet. The DP consisted of a mixture of 14 g de dehydrated nopal, 4 g of chia, 25 g of soy protein, 14 g of oat, 4 g of inulin, 0.15 of flavoring. The placebo (P) consisted of 30 g of calcium caseinate, 30 g of maltodextrin and 0.2 g of flavoring. The kcal, appearance, and flavor were similar in DP and P. The DP and P were given in a package in the dehydrated form ready to be dissolved in water. The DP was divided into two packages, the first package contained 17.3 g of DP or P given in the breakfast and dissolved in 250 ml and the second package was given at the dinner time, and contained 34.7 g of P and DP dissolved in 300 ml of water. Dietary compliance. Dietary compliance was assessed with a 24-h dietary recall and 3-d food record (food lo), during each visit that was analyzed by food processor nutrition analysis software. The compliance of the consumption of the DP or P was evaluated with the number of empty packages returned at the following visit. Physical activity was assessed using the International physical activity questionnaire (IPAQ)
Nimbe Torres y Torres
Mexico City, Please Select An Option Below, Mexico
Intestinal microbiota
Fecal samples were collected to isolate DNA and sequenced using the Illumina platform
Time frame: change after 2.5 months of dietary intervention with respect to baseline
glucose
serum glucose (mg/dl)
Time frame: change after 2.5 months of dietary intervention with respect to baseline
insulin
serum insulin (µU/ml)
Time frame: change after 2.5 months of dietary intervention with respect to baseline
glycated hemoglobin
plasma glycated hemoglobin (HbA1c) (%)
Time frame: change after 2.5 months of dietary intervention with respect to baseline
triglycerides
serum triglycerides (mg/dl)
Time frame: change after 2.5 months of dietary intervention with respect to baseline
cholesterol
serum total cholesterol (mg/dl)
Time frame: change after 2.5 months of dietary intervention with respect to baseline
LDL cholesterol
serum LDL- cholesterol (mg/dl)
Time frame: change after 2.5 months of dietary intervention with respect to baseline
HDL cholesterol
serum HDL- cholesterol (mg/dl)
Time frame: change after 2.5 months of dietary intervention with respect to baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
72
LPS
lipopolysaccharide (LPS) (ng/ml)
Time frame: change after 2.5 months of dietary intervention with respect to baseline
CRP
serum C reactive protein (CRP) (mg/dl)
Time frame: change after 2.5 months of dietary intervention with respect to baseline